Shares of OpGen, Inc. (NASDAQ:OPGN) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price objective of $1.50 for the company and are forecasting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned OpGen an industry rank of 177 out of 265 based on the ratings given to related companies.

A number of research firms have recently issued reports on OPGN. Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, September 13th. HC Wainwright restated a “buy” rating and issued a $1.00 price target on shares of OpGen in a research note on Monday, September 11th.

OpGen (OPGN) traded down $0.01 during mid-day trading on Friday, hitting $0.22. The stock had a trading volume of 489,900 shares, compared to its average volume of 1,131,787. OpGen has a 52-week low of $0.20 and a 52-week high of $3.10. The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. boosted its stake in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.21% of the company’s stock.

WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/opgen-inc-opgn-given-consensus-rating-of-strong-buy-by-brokerages/1761780.html.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.